Titan Pharmaceuticals Appoints Brynner Chiam as Acting Principal Executive Officer and Principal Financial Officer

On November 6, 2024, Titan Pharmaceuticals Inc. (NASDAQ: TTNP) made an important announcement through a Form 8-K filing with the U.S. Securities and Exchange Commission. The company’s Board of Directors has appointed Brynner Chiam, a current director of Titan Pharmaceuticals, as the acting principal executive officer and acting principal financial officer of the company. Mr. Chiam will retain his position on the Board of Directors while fulfilling these additional roles. Titan Pharmaceuticals has initiated a search to secure a full-time chief executive officer to lead the company.

Mr. Chiam, aged 47, brings a wealth of experience to his new dual role at Titan Pharmaceuticals. Besides his position on the company’s Board of Directors, he currently serves as the Tax Director at Black Chamber Management, a shared service company offering outsourcing services to related and third-party companies. His responsibilities at Black Chamber Management include managing financial activities for the company and its clients. Mr. Chiam previously held a directorial position at Tricor Taxand, a professional tax firm, and has experience with PricewaterhouseCoopers (PWC) in Singapore and an investment bank in Malaysia. His extensive background as a tax consultant and practitioner spanning over 20 years, along with his qualifications from Massey University in New Zealand, led the Company’s Board of Directors to believe that he is well-suited to take on the roles of acting principal executive officer and acting principal financial officer.

It is essential to note that there is no formal arrangement or familial relationship influencing Mr. Chiam’s appointment to these key leadership roles within Titan Pharmaceuticals. Moreover, there have been no transactions between Mr. Chiam and the company that necessitate reporting under Item 404(a) of Regulation S-K.

In other news, Titan Pharmaceuticals’ Form 8-K filing did not include any additional financial statements or exhibits beyond the required Cover Page Interactive Data File.

This update signifies a notable change in senior leadership at Titan Pharmaceuticals and underlines the company’s commitment to a diligent and thorough selection process for key executive positions. Investors and industry observers will be keen to monitor the company’s progress as Mr. Chiam assumes his new responsibilities.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Titan Pharmaceuticals’s 8K filing here.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.